Insider Cluster (2 insiders) ·Filed Jun 11, 2026

INM

InMed Pharmaceuticals Inc.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago
Insider cluster: 2 insiders, $189K total
Actionable Insight ▲ Bullish

The magnitude of this cluster buy (4.7% of market cap from two 10% owners) is a strong bullish signal at a micro-cap with no analyst support. Monitor for upcoming press releases, pipeline updates, or financing announcements — the insiders may be positioning ahead of material news. The stock's low liquidity means even small volume could amplify moves.

DirectionBullish
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
INM ▼ -12.66% at T+60d
LONG call ✗ call lost -12.66% · α vs SPY -17.05% · entry $1.58 → $1.38
Entry anchored
Jun 10, 03:58 PM ET
via exchange tick
T+1d
-4.43%
call -4.43% · α -4.97%
$1.51
settled 4mo ago
T+5d
-5.70%
call -5.70% · α -6.13%
$1.49
settled 4mo ago
T+20d
+5.06%
call +5.06% · α +3.17%
$1.66
settled 3mo ago
T+60d
-12.66%
call -12.66% · α -17.05%
$1.38
settled 28d ago

Price Chart

Loading chart...

Executive Summary

Two 10% owners (Vivo Opportunity, LLC and ADAR1 Capital Management, LLC) purchased a combined $189K of INM stock in an 8-day window, representing ~4.7% of the company's $4M market cap. This is a highly material cluster buy from sophisticated investors at a micro-cap pharma with no analyst bullish coverage, suggesting conviction ahead of a potential catalyst.

Key Financial Metrics

Direction
buying
Total Value
$189.0K
Insiders
2

Key Facts

  • Two 10% owners bought $189K total in open-market purchases over 8 days (May 13–20, 2026).
  • Total buy value equals ~4.7% of INM's $4M market cap, far exceeding the 2% materiality threshold.
  • Vivo Opportunity, LLC bought 51.1K shares at $1.56 ($80K) on May 20.
  • ADAR1 Capital Management, LLC bought 68.6K shares at $1.60 ($110K) on May 19.
  • INM has zero analyst buy ratings (3 Hold, 5 Sell/Strong Sell) and a $4M market cap.
  • Historical calibration shows cluster buys at this size are amplified by cross-filing context (all 22 rule pairs are amplifiers).

Financial Impact

$189K in insider purchases = 4.7% of $4M market cap

insider ownershipmarket cap

Risk Factors

  • Micro-cap pharma with $4M market cap is highly speculative and illiquid.
  • No analyst bullish coverage and 5 sell/strong sell ratings indicate fundamental challenges.
  • Historical T+20 performance on INM reports shows -29.76% average return, suggesting the stock has been a poor performer after prior signals.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-INM-1781140524722
13 reports for INM
Performance horizon
75% Hit rate 6 of 8 directional calls best @ T+5▲ +19.19%Mar 20, 2026
Filters
Rows
Reports for INM — sortable, filterable
TypeNow
Sep 9, 2026
23d ago
425
NEUTRAL ★ 6/10
$1.31 $1.39▲ +6.11%▲ +6.61%$1.33 (+1.53%)
Jul 10, 2026
12w ago
8-K
BEARISH ★ 6/10
$1.57 $1.52▲ +3.18%▲ +2.40%$1.33 (+15.29%)
Jul 2, 2026
13w ago
S-4
BEARISH ★ 7/10
$1.56 $1.66▼ −6.41%▼ −5.48%$1.33 (+14.74%)
Jun 11, 2026
16w ago
Insider Cluster
BULLISH ★ 7/10
$1.58 $1.49▼ −5.70%▼ −6.13%$1.33 (−15.82%)
Jun 10, 2026
16w ago
8-K
NEUTRAL ★ 4/10
$1.51 $1.48▼ −1.99%▼ −5.42%$1.33 (−11.92%)
May 19, 2026
19w ago
425
MIXED ★ 7/10
$1.60 $1.69▲ +5.63%▲ +3.38%$1.33 (−16.87%)
May 19, 2026
19w ago
8-K
BULLISH ★ 8/10
$1.60 $1.69▲ +5.63%▲ +3.38%$1.33 (−16.87%)
May 19, 2026
19w ago
8-K
BEARISH ★ 7/10
$1.60 $1.66▼ −3.75%▼ −1.45%$1.33 (+16.87%)
Apr 27, 2026
22w ago
8-K
BEARISH ★ 8/10
$0.7010 $0.7480▼ −6.70%▼ −5.01%$1.33 (−89.73%)
Apr 3, 2026
26w ago
8-K
NEUTRAL ★ 3/10
$0.6950 $0.7130▲ +2.59%▼ −1.54%$1.33 (+91.37%)
Showing 10 of 13

US Market Status

Market Closed — Opens Mon (64h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 11, 2026